Table 3.
Comparison of DFS stratified by genotype and treatment group
| Gene/SNP | Sunitinib vs. Placebo: HR (95% CI); P Unadjusted | ||
|---|---|---|---|
| VEGFA rs699947 | A/A 0.78 (0.33–1.87); 0.579 |
A/C 0.65 (0.39–1.10); 0.107 |
C/C 0.81 (0.41–1.61); 0.547 |
| VEGFA rs833061 | C/C 0.78 (0.33–1.87); 0.579 |
C/T 0.65 (0.39, 1.08); 0.094 |
T/T 0.83 (0.41–1.68); 0.604 |
| VEGFR1 rs9554320 | A/A 1.32 (0.42–4.20); 0.636 |
A/C 0.85 (0.54–1.36); 0.507 |
C/C 0.44 (0.21–0.91); 0.023 |
| VEGFR1 rs9582036 | C/C 0.77 (0.08–7.49); 0.825 |
C/A 0.98 (0.61–1.59); 0.945 |
A/A 0.56 (0.30–1.02); 0.054 |
| VEGFR2 rs2071559 | T/T 0.46 (0.23–0.90); 0.020 |
T/C 1.03 (0.60–1.78); 0.914 |
C/C 0.72 (0.33–1.58); 0.417 |
| VEGFR2 rs1870377 | A/A Not donea |
A/T 0.74 (0.39–1.40); 0.357 |
T/T 0.70 (0.43–1.15); 0.161 |
| VEGFR3 rs6877011 | C/C 0.72 (0.48–1.06); 0.096 |
C/G 1.38 (0.48–4.01); 0.550 |
G/G Not donea |
| LOXL2 rs4872122 | A/A 0.81 (0.37–1.75); 0.589 |
A/C 0.72 (0.41–1.26); 0.245 |
C/C 0.75 (0.39–1.44); 0.388 |
| eNOS rs2070744 | T/T 0.53 (0.30–0.94); 0.028 |
T/C 0.96 (0.55–1.66); 0.879 |
C/C 0.85 (0.26–2.80); 0.794 |
| SH3GL2 rs10963287 | C/C 0.82 (0.50–1.32); 0.407 |
C/T 0.56 (0.28–1.10); 0.088 |
T/T 0.94 (0.29–3.10); 0.920 |
| CCDC26 rs60315789 | –/– 0.56 (0.24–1.28); 0.161 |
–/TAT 0.66 (0.38–1.12); 0.117 |
TAT/TAT 1.06 (0.53–2.10); 0.874 |
HR calculated using the unstratified Cox proportional hazards model. Two-sided P value from the unstratified log-rank test.
a
Due to events <10 in both comparison groups.